161 related articles for article (PubMed ID: 37013921)
21. Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
Tan AT; Schreiber S
Antiviral Res; 2020 Apr; 176():104748. PubMed ID: 32087191
[TBL] [Abstract][Full Text] [Related]
22. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of hepatocellular carcinoma.
Butterfield LH; Ribas A
Expert Opin Biol Ther; 2002 Feb; 2(2):123-33. PubMed ID: 11849113
[TBL] [Abstract][Full Text] [Related]
24. A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection.
Kilickap S; Kars A; Hamaloglu E; Simsek H
Med Oncol; 2009 Dec; 26(4):501-5. PubMed ID: 19688614
[TBL] [Abstract][Full Text] [Related]
25. Clinical features of hepatitis B virus-related hepatocellular carcinoma.
Ishikawa T
World J Gastroenterol; 2010 May; 16(20):2463-7. PubMed ID: 20503445
[TBL] [Abstract][Full Text] [Related]
26. Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.
Ijichi H; Yoshizumi T; Ikegami T; Soejima Y; Ikeda T; Kawanaka H; Uchiyama H; Yamashita Y; Morita M; Oki E; Mimori K; Sugimachi K; Saeki H; Watanabe M; Shirabe K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):376-82. PubMed ID: 24511669
[TBL] [Abstract][Full Text] [Related]
27. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.
Park JW; Park KW; Cho SH; Park HS; Lee WJ; Lee DH; Kim CM
Am J Gastroenterol; 2005 Oct; 100(10):2194-200. PubMed ID: 16181368
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
Li X; Zhong X; Chen ZH; Wang TT; Ma XK; Xing YF; Wu DH; Dong M; Chen J; Ruan DY; Lin ZX; Wen JY; Wei L; Wu XY; Lin Q
Asian Pac J Cancer Prev; 2015; 16(18):8665-70. PubMed ID: 26745134
[TBL] [Abstract][Full Text] [Related]
30. Molecular targets for therapy of hepatitis B virus-induced hepatocellular carcinoma.
Tharayil VS; Roberts LR
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):387-406. PubMed ID: 17108869
[TBL] [Abstract][Full Text] [Related]
31. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
[TBL] [Abstract][Full Text] [Related]
32. Chronic hepatitis B and hepatocellular carcinoma.
McClune AC; Tong MJ
Clin Liver Dis; 2010 Aug; 14(3):461-76. PubMed ID: 20638025
[TBL] [Abstract][Full Text] [Related]
33. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT; Meng F; Jin J; Zhang JY; Wang SY; Shi L; Shi M; Li Y; Xie Y; Liu LM; Zhou CB; Chua A; Ho ZZ; Luan J; Zhao J; Li J; Wai LE; Koh S; Wang T; Bertoletti A; Wang FS
Hepatol Commun; 2022 Apr; 6(4):841-854. PubMed ID: 34935312
[TBL] [Abstract][Full Text] [Related]
34. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic strategies for hepatitis B virus-associated hepatocellular carcinoma.
Wong ET; Chew YP; Lee LA; Lee CG
Curr Drug Targets; 2002 Oct; 3(5):369-78. PubMed ID: 12182228
[TBL] [Abstract][Full Text] [Related]
36. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Asghar K; Farooq A; Zulfiqar B; Rashid MU
World J Gastroenterol; 2017 Apr; 23(13):2286-2293. PubMed ID: 28428708
[TBL] [Abstract][Full Text] [Related]
37. NK cells in hepatitis B virus infection: a potent target for immunotherapy.
Shabani Z; Bagheri M; Zare-Bidaki M; Hassanshahi G; Arababadi MK; Mohammadi Nejad M; Kennedy D
Arch Virol; 2014 Jul; 159(7):1555-65. PubMed ID: 24445811
[TBL] [Abstract][Full Text] [Related]
38. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw.
Tsubota A; Arase Y; Ren F; Tanaka H; Ikeda K; Kumada H
J Med Virol; 2001 Oct; 65(2):257-65. PubMed ID: 11536231
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
Jachs M; Scheiner B; Pinter M
J Hepatol; 2022 Jul; 77(1):256-257. PubMed ID: 35124108
[No Abstract] [Full Text] [Related]
40. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.
Lin XJ; Lao XM; Shi M; Li SP
Dig Dis Sci; 2016 Sep; 61(9):2465-76. PubMed ID: 27105647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
